Drug
Exatecan clinical trials
- studies test it
- 15
- open now
- 0
- in phase 3
- 1
- first study started
- 1999
How studies write it
Studies that test it under each name
Name
Studies by the year they started
15 studies that test it; most in 1999 (7)
| Year | Studies |
|---|---|
| 1999 | 7 |
| 2000 | 2 |
| 2001 | 2 |
| 2002 | 2 |
| 2003 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 2
- Phase 2
- 12
- Phase 3
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 13 · Other 2
Daiichi Sankyo (12) · Daiichi Pharmaceuticals (1) · Jonsson Comprehensive Cancer Center (1) · European Organisation for Research and Treatment of Cancer - EORTC (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses exatecan is read from its arms, and is right about nine times in ten.
Testing it · 15
- DX-8951f in Treating Previously Untreated Patients With Stage IIIB or Stage IV Non-small Cell Lung CancerCompletedPhase 2Daiichi PharmaceuticalsNCT00005091Written as exatecan mesylate
- Exatecan Mesylate in Treating Patients With Advanced Solid Tumors and Kidney DysfunctionCompletedPhase 1Jonsson Comprehensive Cancer CenterNCT00045318Written as exatecan mesylate
- Exatecan Mesylate in Treating Patients With Advanced Soft Tissue SarcomaCompletedPhase 2European Organisation for Research and Treatment of Cancer - EORTCNCT00041236Written as exatecan mesylate
- Chemotherapy in Treating Patients With Recurrent, Metastatic, or Unresectable Ovarian, Fallopian Tube, or Peritoneal CancerCompletedPhase 2Daiichi SankyoNCT00004060Written as exatecan mesylate
- DX-8951f in Treating Women Who Have Advanced or Recurrent Cancer of the CervixCompletedPhase 2Daiichi SankyoNCT00004866Written as exatecan mesylate
- Chemotherapy in Treating Women With Metastatic Breast CancerCompletedPhase 2Daiichi SankyoNCT00004046Written as exatecan mesylate
- Exatecan Mesylate in Treating Children With Relapsed or Refractory RhabdomyosarcomaCompletedPhase 2Daiichi SankyoNCT00055939Written as exatecan mesylate
- Gemcitabine With or Without Exatecan Mesylate in Treating Patients With Locally Advanced or Metastatic Pancreatic CancerCompletedPhase 3Daiichi SankyoNCT00023972Written as exatecan mesylate
- DX-8951f in Treating Patients With Metastatic Stomach CancerCompletedPhase 2Daiichi SankyoNCT00017212Written as exatecan mesylate
- DX-8951f in Treating Patients With Liver CancerCompletedPhase 2Daiichi SankyoNCT00004108Written as exatecan mesylate
- Exatecan Mesylate in Treating Patients With Ewing's Sarcoma, Primitive Neuroectodermal Tumor, or Desmoplastic Small Round Cell TumorCompletedPhase 2Daiichi SankyoNCT00055952Written as exatecan mesylate
- DX-8951f in Treating Patients With Biliary CancerCompletedPhase 2Daiichi SankyoNCT00005938Written as exatecan mesylate
- Chemotherapy in Treating Patients Who Have Hematologic CancerCompletedPhase 1Daiichi SankyoNCT00004047Written as exatecan mesylate
- DX-8951f in Treating Patients With Metastatic Cancer of the PancreasCompletedPhase 2Daiichi SankyoNCT00003951Written as exatecan mesylate
- Chemotherapy in Treating Patients With Prostate CancerCompletedPhase 2Daiichi SankyoNCT00004045Written as exatecan mesylate
Codes
What other systems call exatecan · ClinicalTrials.gg INT003870
- MeSH (NLM) C095887exatecanConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) OC71PP0F89EXATECANConfirmed FDA, NLM, Wikidata
- Wikidata Q5419343exatecanConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C66720ExatecanOne source FDA
- DrugBank DB12185One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C095887 | exatecan | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | OC71PP0F89 | EXATECAN | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q5419343 | exatecan | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C66720 | Exatecan | One source FDA |
| DrugBank | DB12185 | — | One source Wikidata |
Also registered as exatecan mesylate (UNII D2VJ1CC26Q).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.